FIELD: chemical engineering; pharmaceutical engineering.
SUBSTANCE: method involves applying substances of macrolide group showing high inhibition degree with respect to protein of tyrosine kinase.
EFFECT: enhanced effectiveness in suppressing infection and proliferation of human immune deficiency virus in macrophages.
4 cl, 25 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IDENTIFYING FUNCTIONAL M1 AND M2 PHENOTYPE OF HUMAN MACROPHAGES GENERATED IN VITRO FROM BLOOD MONOCYTES | 2019 |
|
RU2717024C1 |
| METHOD FOR MODELLING AIDЪS INFECTIONS | 0 |
|
SU1837355A1 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING VIRAL INFECTION | 2016 |
|
RU2723016C2 |
| METHODS OF TREATING HIV-1 INFECTION | 2020 |
|
RU2827716C1 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| COMPLEX ANTI-HIV COMPOUND | 2004 |
|
RU2270690C1 |
| COMPLEX AUTOLOGICAL VACCINE AGAINST HIV INFECTION AND AIDS | 2005 |
|
RU2306950C2 |
| AGENT FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTIONS AND METHOD OF THEIR INHIBITION | 2002 |
|
RU2196602C1 |
| NOVEL QUINOLINE DERIVATIVE FOR USE IN TREATING AND PREVENTING VIRAL INFECTIONS | 2016 |
|
RU2723013C2 |
| CCR5 EXPRESSION SUPRESSION COMPOSITIONS AND METHODS OF APPLICATION THEREOF | 2004 |
|
RU2353357C2 |
Authors
Dates
2005-04-27—Published
2002-11-20—Filed